

# CUBE LABS AT A GLANCE

Cube Labs is an Italian **Venture Builder** specialized in development of projects in the healthcare technologies sector.

The Company is listed on the **Euronext Growth Milan - Professional segment**, dedicated to SMEs with high growth potential, since March 21, 2023.

At IPO, Cube Labs raised €4.1 million following the placement of 2 million shares at 2 euros. Market capitalization at the IPO was 34.105 million euros.

**3 offices** (Milan, Rome, Lecce), **29 professionals**.  
Strategic Advisory Board composed of **12 key people** with international expertise.

## BUSINESS MODEL

Business model focuses on academic R&D projects with high growth potential, aiming to support and enhance them in a medium/long term perspective. As a Venture Builder, Cube Labs supports selected projects from early stage in the following activities:

- **Financial**, ensuring immediate and continuous access to sources of finance;
- **Strategic**, ensuring management support;
- **Operational**, taking an active part in the management of the subsidiary company and providing a wide range of services.

## STRATEGY

In the short term, Cube Labs intends to grow through:

- ▶ The **commercial valorization** of the subsidiary companies, by increasing R&D activity on selected Initiatives.
- ▶ An increase in strategic, operational and financial advice to selected companies.

In the mid/long term, Cube Labs intends to grow through:

- ▶ The **financial valuation of the subsidiary companies**, through corporate finance transactions involving them (e.g. out licensing of individual assets, M&A transactions, IPO).
- ▶ The **expansion of the number of portfolio companies**, relying on the exclusive partnership with INBB.

## BOARD OF DIRECTORS

**Renato Del Grosso**  
Member of the Board &  
Chief Strategy Officer

**Filippo Surace**  
Chairman &  
Chief Executive Officer

**Massimo Fiocchi**  
Member of the Board &  
Chief Financial Officer

**Domenico Colella**  
Non-executive Director

**Mario Matteo Busso**  
Independent Director

## OUR PLAYGROUND

Cube Labs selects R&D projects mainly in the following areas:



## IPO NUMBERS

Number of shares pre-IPO	15,000,000
Shares newly issued	2,052,500
Warrant after conversion (23/10/2023)	1,752,500
Outstanding shares post-IPO*	17,852,500
Free Float	15.98%
IPO Date	21 March 2023
Issue Price (€)	2.00
Market Cap (€/M) @ IPO	34.105
Market	EGM PRO
Title update YoY to 17/05/2024	+5.37%
Last Price to 17/05/2024 (€)	2.16
Market cap to 17/05/2024 (€/M)	38.561

\* On 3 August 2023, the company raised an additional EUR 500,000 in a capital increase. On 21 October 2023, the company raised an additional EUR 500,000 in a capital increase, coming from the «Warrant Cube Labs» conversion. On 21 December 2023, the company raised an additional EUR 500,000 in a capital increase.

## 1H 2023 PORTFOLIO




\* On 6 December 2023, Cube Labs S.p.A. announced the establishment of two new companies: Regenerabioma Srl and Myrtoviva Srl, both not included in Cube Labs' portfolio value.

## 1H 2023 KEY FINANCIALS



## SHAREHOLDING & ORGANIZATION



\* The shareholding of Filippo Surace is 71.32%, of which 61.62% is held through Keltinvest S.r.l., a company that Surace himself controls 100% and of which he is sole director, and the remaining 9.70% directly as a natural person.

\*\* Lock-up until March 21, 2025.

Last updated at 29/01/2024.